TEP1

Across TCGA pan-cancer cohorts, TEP1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TEP1 data layer compared with 25 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TEP1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TEP1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

CCRCC, GBM, and PDAC are the cancer types where TEP1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	IV	0.123	0.785	.009	24	view →
GBM	OS	Median	All	0.376	0.682	.001	18	view →
PDAC	OS	Median	III,IV	0.536	0.306	.021	14	view →
LSCC	DFS	Median	II,III,IV	0.841	1.000	.008	12	view →
UCEC	DFS	Quartile	III,IV	1.000	0.451	.040	4	view →
HNSC	OS	Tertile	All	1.000	0.948	.040	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TEP1–CCRCC (OS)

Open the CCRCC breakdown →